Codes ATC:
J05AR01
EMLc
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Code ICD11:
1C62.Z
INN
Lamivudine + zidovudine
Type de médicament
Chemical agent
Type de liste
Liste de base
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Solid:
30 mg + 60 mg Tablet
(EMLc)
;
150 mg + 300 mg Tablet (EML)
Historique des statuts LME
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Wikipédia
DrugBank
Résumé des preuves et recommandation du comité d'experts
The Expert Committee recommended the removal of lamivudine + zidovudine 150 mg + 300 mg from the EMLc to be in alignment with the recommendations of the Inter-Agency Task Team on Prevention and treatment of HIV in Pregnant Women, Mothers and their Children (1).
References:
1. Update to the optimal list of paediatric ARV formulations. IATT Meeting Report, Geneva, Switzerland, 11-12 September 2013 Geneva: World Health Organization; 2013. Available from: http://apps.who.int/medicinedocs/documents/s21435en/s21435en.pdf.